SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic.

The previously announced date and time of the annual meeting, Monday, May 18, 2020, at 9:00 a.m. PT, has not changed. Stockholders will not be able to attend the annual meeting in person.

Whether or not stockholders plan to virtually attend the annual meeting, Sangamo urges them to vote and submit their proxy in advance of the annual meeting by one of the methods described in the proxy materials for the annual meeting.

The proxy card included with any proxy materials previously distributed will not be updated to reflect the change in location and may continue to be used to vote shares in connection with the annual meeting.

Attending and Voting at the Annual Meeting as a Stockholder of Record

At the time and date of the annual meeting, Sangamo stockholders of record as of March 20, 2020 (the ‘record date’) can attend and vote by accessing the meeting center at and entering the 15-digit control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. The meeting password is SGMO2020. Stockholders of record can vote their shares by clicking on the ‘Cast Your Vote’ link in the meeting center.

Registering to Attend and Vote at the Annual Meeting as a Beneficial Owner

Beneficial stockholders as of the record date (i.e., shares held in ‘street name’ through an intermediary, such as a bank or broker) must register in advance to attend and vote at the annual meeting. To register, stockholders must obtain a legal proxy from the holder of record and submit proof of legal proxy reflecting the number of shares of Sangamo common stock held as of the record date, along with name and email address, to Computershare at . Requests for registration must be labeled as “Legal Proxy” and must be received no later than Wednesday, May 13, 2020, 2:00 p.m. PT. Stockholders will then receive a confirmation of registration with a control number by email from Computershare. At the time and date of the annual meeting, registered beneficial stockholders can attend by accessing the meeting center at and entering the 15-digit control number received by email. The meeting password is SGMO2020. Registered beneficial owners can vote their shares by clicking on the ‘Cast Your Vote’ link in the meeting center.

Attending the Annual Meeting as a Guest

At the time and date of the annual meeting, guests can attend by accessing the meeting center at , clicking on the “I am a Guest” button and entering the information requested on the following screen.

Asking Questions

Stockholders of record and registered beneficial owners can submit questions to Sangamo’s representatives in the meeting center.

List of Stockholders of Record

At the time and date of the annual meeting, stockholders will be able to inspect a list of stockholders of record in the meeting center for any purpose germane to the annual meeting. Stockholders may also request to view a list of stockholders of record for ten days prior to the annual meeting by sending an email to .

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. For more information about Sangamo, visit .

EN
07/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sangamo Therapeutics Inc.

 PRESS RELEASE

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR ...

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed can serve as primary basis of approval ...

 PRESS RELEASE

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten O...

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.4719. The combined offering price o...

 PRESS RELEASE

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA f...

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway  Isaralgagene civaparvovec continues to show favorable safety and tolerability profile Sangamo expects to complete Biological License Application (BLA) submission under accelerated approval pathway in second quarter of 2026...

 PRESS RELEASE

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-5...

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. Fast Track Designation aims to facilitate the development and expedite the review of new the...

 PRESS RELEASE

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submissio...

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. This acceptance follows Sangamo’s meeting with the FDA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch